NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses research regarding novel relapsed refractory multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.
One study highlighted by Banerjee, an assistant professor at the University of Washington, explored dosing of mezigdomide and dexamethasone in patients with triple-class refractory multiple myeloma. The overall response rate was found to be 40.6% in all patients, but importantly, in those who had received prior anti-B-cell maturation antigen therapy, the overall response rate was 50%,
